当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Abstract：

:Numerous studies have demonstrated that angiogenesis and in particular VEGF over-expression play an essential role in the progression and metastatic potential of breast cancer. Bevacizumab is a humanized recombinant monoclonal antibody that specifically blocks the binding of VEGF to high-affinity receptors and it has been recently used for the treatment of metastatic breast cancer. We conducted a meta-analysis to synthesize available evidence for use of bevacizumab in metastatic breast cancer patients. Systematic review and meta-analysis of available trials. Primary outcomes were overall survival, progression free survival (PFS) and objective response rate (ORR). Five trials were identified with 3,163 eligible patients. Combination of bevacizumab and chemotherapy resulted in a statistically significant improvement in PFS (HR = 0.70, 95% CI 0.60-0.82, P = 9.3 x 10(-6)) and ORR (RR = 1.26, 95% CI 1.17-1.37, P = 9.96 x 10(-9)) compared with chemotherapy alone. Differences in objective response rates were substantial independently by the type of chemotherapy used, while PFS advantages were observed only for taxanes. The pooled HR for overall survival did not show significant advantage for the use of bevacizumab compared to placebo arm (HR = 0.90, 95% CI 0.80-1.03, P = 0.119). This meta-analysis shows that the addition of bevacizumab to chemotherapy offers meaningful improvement in PFS and ORR in patients with metastatic breast cancer. Bevacizumab treatment might be suggested for treatment of 1st line metastatic breast cancer, but more data are needed until statistical overall survival differences will be documented and firm guideline recommendation could be given.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Valachis A,Polyzos NP,Patsopoulos NA,Georgoulias V,Mavroudis D,Mauri D

doi

10.1007/s10549-009-0727-0

subject

Has Abstract

pub_date

2010-07-01 00:00:00

pages

1-7

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

122

pub_type

杂志文章,meta分析,评审

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Ethnic differences in risk perception among women at increased risk for breast cancer.

    abstract：:There has been increasing interest in the role of cultural and ethnic factors in breast cancer risk perceptions and screening practices. This study examined ethnic differences in breast cancer risk perception in 112 African American and 224 white women ages 35 and older who had at least one first-degree relative diagn...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/BF01806000

    authors： Hughes C,Lerman C,Lustbader E

    更新日期：1996-01-01 00:00:00

  • Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

    abstract：:Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3554-5

    authors： Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

    更新日期：2015-09-01 00:00:00

  • The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

    abstract：:The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to predict recurrence-free survival (RFS) in triple-negative (TN) breast cancer. It was at least as accurate as the standard binary system, the absence or presenc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3510-4

    authors： Jebbink M,van Werkhoven E,Mandjes IA,Wesseling J,Lips EH,Vrancken Peeters MJ,Loo CE,Sonke GS,Linn SC,Falo Zamora C,Rodenhuis S

    更新日期：2015-08-01 00:00:00

  • Phase II study of amonafide in advanced breast cancer.

    abstract：:Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks. Five objective tumour responses of 5.0 month...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01833358

    authors： Scheithauer W,Dittrich C,Kornek G,Haider K,Linkesch W,Gisslinger H,Depisch D

    更新日期：1991-12-01 00:00:00

  • False-negative rate of combined mammography and ultrasound for women with palpable breast masses.

    abstract：:Mammography and ultrasound are often used concurrently for patients with palpable breast masses. While mammography has a false-negative rate of approximately 15 %, the addition of breast ultrasound decreases this rate among patients with palpable breast masses. There are no recent outcome data regarding the use of com...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3557-2

    authors： Chan CH,Coopey SB,Freer PE,Hughes KS

    更新日期：2015-10-01 00:00:00

  • Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

    abstract：:We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but n...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806133

    authors： Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

    更新日期：1987-10-01 00:00:00

  • Health-related quality of life before and after a breast cancer diagnosis.

    abstract：:While many reports describe health-related quality of life (QOL) among breast cancer survivors, few compare QOL before and after diagnosis and whether changes in QOL substantially differ from changes experienced by all women during aging. QOL was examined in a cohort of female residents of Beaver Dam, Wisconsin, aged ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9653-1

    authors： Trentham-Dietz A,Sprague BL,Klein R,Klein BE,Cruickshanks KJ,Fryback DG,Hampton JM

    更新日期：2008-05-01 00:00:00

  • Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

    abstract：:Multiple adjuvant regimens are used for HER2+ breast cancer, but experience in routine practice is not reported. We evaluated whether oncologists' perceptions of these regimens matches clinical experience. We surveyed Wisconsin medical oncologists throughout the state regarding factors impacting selection of TCH (doce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1862-y

    authors： Rocque G,Onitilo A,Engel J,Pettke E,Boshoven A,Kim K,Rishi S,Waack B,Wisinski KB,Tevaarwerk A,Burkard ME

    更新日期：2012-01-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract：:In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00713399

    authors： Jordan VC

    更新日期：1995-01-01 00:00:00

  • Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas.

    abstract：:The expression of amphiregulin (AR), heregulin (HRG), and cripto-1 (CR-1) mRNA transcripts was assessed in 60 human primary breast carcinoma. AR and HRG transcripts were expressed respectively in 58% and 25% of the carcinomas as measured by Northern blot analysis. CR-1 mRNA was found in 77% of the carcinomas using Rev...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00665981

    authors： Normanno N,Kim N,Wen D,Smith K,Harris AL,Plowman G,Colletta G,Ciardiello F,Salomon DS

    更新日期：1995-09-01 00:00:00

  • Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.

    abstract：PURPOSE:Immunotherapy has recently been shown to improve outcomes for advanced PD-L1-positive triple-negative breast cancer (TNBC) in the Impassion130 trial, leading to FDA approval of the first immune checkpoint inhibitor in combination with taxane chemotherapy. To further develop predictive biomarkers and improve the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05936-4

    authors： Deng J,Thennavan A,Shah S,Bagdatlioglu E,Klar N,Heguy A,Marier C,Meyn P,Zhang Y,Labbe K,Almonte C,Krogsgaard M,Perou CM,Wong KK,Adams S

    更新日期：2021-01-01 00:00:00

  • Galectin-3 and L1 retrotransposons in human breast carcinomas.

    abstract：:Galectin-3 is a galactoside binding protein found at elevated levels in a wide variety of neoplastic cells and thought to be involved in cognitive cellular interactions during transformation and metastasis. Previously, we have shown that introduction of human galectin-3 (Mr 31,000) cDNA into the human breast cancer ce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005913810250

    authors： Nangia-Makker P,Sarvis R,Visscher DW,Bailey-Penrod J,Raz A,Sarkar FH

    更新日期：1998-05-01 00:00:00

  • Ha-ras rare alleles in breast cancer susceptibility.

    abstract：:Over the last several years, evidence has accumulated to support the idea that rare Ha-ras polymorphisms are associated with inherited susceptibility to certain human cancers. A recent epidemiologic study conducted at our institution found a significant association specifically with breast cancer, although the mechani...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00694750

    authors： Conway K,Edmiston S,Fried DB,Hulka BS,Garrett PA,Liu ET

    更新日期：1995-07-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract：:Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3608-8

    authors： Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期：2015-11-01 00:00:00

  • Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

    abstract：:Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women in...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s10549-009-0309-1

    authors： Henry NL,Rae JM,Li L,Azzouz F,Skaar TC,Desta Z,Sikora MJ,Philips S,Nguyen AT,Storniolo AM,Hayes DF,Flockhart DA,Stearns V,Consortium on Breast Cancer Pharmacogenomics Investigators.

    更新日期：2009-10-01 00:00:00

  • Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase.

    abstract：:Resveratrol is a natural polyphenolic compound and has been shown to exhibit cardio-protective as well as anti-neoplastic effects on various types of cancers. However, the exact mechanism of its anti-tumor effect is not clearly defined. Resveratrol has been shown to have strong hypolipidemic effect on normal adipocyte...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1300-6

    authors： Pandey PR,Okuda H,Watabe M,Pai SK,Liu W,Kobayashi A,Xing F,Fukuda K,Hirota S,Sugai T,Wakabayashi G,Koeda K,Kashiwaba M,Suzuki K,Chiba T,Endo M,Fujioka T,Tanji S,Mo YY,Cao D,Wilber AC,Watabe K

    更新日期：2011-11-01 00:00:00

  • Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

    abstract：PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 pat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05479-3

    authors： Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

    更新日期：2020-01-01 00:00:00

  • Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

    abstract：PURPOSE:The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. METHODS:Of the 53,670 patients registered between 2004 and 2006 and su...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3984-8

    authors： Kataoka A,Iwamoto T,Tokunaga E,Tomotaki A,Kumamaru H,Miyata H,Niikura N,Kawai M,Anan K,Hayashi N,Masuda S,Tsugawa K,Aogi K,Ishida T,Masuoka H,Iijima K,Kinoshita T,Nakamura S,Tokuda Y

    更新日期：2016-11-01 00:00:00

  • Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?

    abstract：PURPOSE:We sought to determine if bioimpedance spectroscopy (BIS) measurements can accurately assess changes in breast cancer-related lymphedema (BCRL) in patients undergoing lymphovenous bypass (LVB). METHODS:Patients undergoing LVB for BCRL refractory to conservative treatment from 1/2015 to 12/2018 were identified ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-06059-6

    authors： Sutherland A,Wagner JL,Korentager S,Butterworth J,Amin AL,Balanoff CR,Hangge A,Larson KE

    更新日期：2021-01-04 00:00:00

  • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

    abstract：:Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-012-2003-y

    authors： Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

    更新日期：2012-06-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.

    abstract：:A model for a more precise prognosis of the risk of relapse is needed to avoid overtreatment of lymph node-negative breast cancer patients. A large derivation data set (n = 684) was generated by pooling three independent breast cancer expression microarray data sets. Two major prognostic factors, proliferation and imm...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1626-8

    authors： Oh E,Choi YL,Park T,Lee S,Nam SJ,Shin YK

    更新日期：2012-04-01 00:00:00

  • Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

    abstract：:Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer; however, it is still unclear which signaling pathways are the major drivers of tamoxifen-resistant growth. To characterize resistance mechanisms, we have generated different tamoxifen-resistant breast cancer cell lines from MCF-7....

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2485-2

    authors： Thrane S,Lykkesfeldt AE,Larsen MS,Sorensen BS,Yde CW

    更新日期：2013-05-01 00:00:00

  • Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS).

    abstract：:Whether wide excision with margins ≥1 cm is sufficient treatment for small low- or intermediate-grade ductal carcinoma in situ (DCIS) is unclear. This is an updated analysis of a phase II, single-arm, prospective trial testing this hypothesis. A total of 158 patients with low- or intermediate-grade DCIS who underwent ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2813-6

    authors： Wong JS,Chen YH,Gadd MA,Gelman R,Lester SC,Schnitt SJ,Sgroi DC,Silver BJ,Smith BL,Troyan SL,Harris JR

    更新日期：2014-01-01 00:00:00

  • Factors influencing the use of extended adjuvant endocrine therapy.

    abstract：PURPOSE:Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05145-8

    authors： Kadakia KC,Kidwell KM,Barton DL,Schott AF,Hayes DF,Griggs JJ,Henry NL

    更新日期：2019-05-01 00:00:00

  • Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.

    abstract：PURPOSE:Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffin-embedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3971-0

    authors： Wong EM,Joo JE,McLean CA,Baglietto L,English DR,Severi G,Wu HC,Terry MB,Hopper JL,Milne RL,Giles GG,Southey MC

    更新日期：2016-11-01 00:00:00

  • Prognostic impact of breast cancer subtypes in elderly patients.

    abstract：:We aimed to analyse the impact of breast cancer (BC) subtypes on the clinical course of disease with special emphasis on the occurrence of brain metastases (BM) and outcome in an elderly BC population. A total number of 706 patients ≥65 years receiving treatment for BC from 2007 to 2011 were identified from a BC datab...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3787-y

    authors： Bergen ES,Tichy C,Berghoff AS,Rudas M,Dubsky P,Bago-Horvath Z,Mader RM,Exner R,Gnant M,Zielinski CC,Steger GG,Preusser M,Bartsch R

    更新日期：2016-05-01 00:00:00

  • Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.

    abstract：:BRCAness breast tumors represent a group of sporadic tumors characterized by a reduction in BRCA1 gene expression. As BRCA1 is involved in double-strand breaks (DSBs) repair, dysfunctional BRCA pathway could make a tumor sensitive to DNA damaging drugs (e.g., platinum agents). Thus, accurately identifying BRCAness cou...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3648-0

    authors： Branham MT,Campoy E,Laurito S,Branham R,Urrutia G,Orozco J,Gago F,Urrutia R,Roqué M

    更新日期：2016-01-01 00:00:00

  • Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis.

    abstract：:Old age is associated with comorbidity and decreased functioning which influences treatment decisions in elderly breast cancer patients. The purpose of this study was to identify risk factors for complications after breast cancer surgery in elderly patients, and to assess mortality in patients with postoperative compl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2462-9

    authors： de Glas NA,Kiderlen M,Bastiaannet E,de Craen AJ,van de Water W,van de Velde CJ,Liefers GJ

    更新日期：2013-04-01 00:00:00

  • Transcriptional profiles of progestogen effects in the postmenopausal breast.

    abstract：:Estrogen plus progestin hormone therapy has been associated with increased breast proliferation, breast density, and breast cancer risk in postmenopausal women, beyond that seen with estrogen alone. The goal of this study was to evaluate progestogen effects on gene expression profiles in the breast contributing to thi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0003-8

    authors： Wood CE,Register TC,Cline JM

    更新日期：2009-03-01 00:00:00